8-K: Lineage Cell Therapeutics Closes $6 Million Second Tranche of Registered Direct Offering, Potentially Receiving Additional $36 Million from Warrant Exercises

Lineage Cell Therapeutics finalized the second tranche of its registered direct offering, securing $6 million and anticipating up to $36 million more from warrant exercises linked to a clinical milestone.

Summary

• Lineage Cell Therapeutics closed the second tranche of its registered direct offering, receiving $6 million in gross proceeds.
• This follows the $24 million received in the first tranche in November 2024, bringing the total to $30 million.
• The company may receive up to an additional $36 million if warrants issued in the offering are fully exercised on a cash basis.
• The warrants are linked to a clinical milestone related to advancing OpRegen into a multi-center phase 2 or 3 clinical trial.
• Shareholders approved the issuance of 7,894,737 common shares and warrants to Broadwood Partners, L.P., at a combined price of $0.76 per share and warrant.
• The warrants are exercisable at $0.91 per share, starting May 21, 2025, and expire on May 21, 2028, or 90 days after public disclosure of the OpRegen milestone.
• Lineage plans to use the net proceeds for working capital, general corporate purposes, research and development, and capital expenditures.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company successfully closed a funding round, securing additional capital. However, the reliance on warrant exercises and the achievement of a clinical milestone introduce uncertainty.

Positives

• Lineage Cell Therapeutics successfully closed the second tranche of its registered direct offering, securing additional funding.
• The potential for an additional $36 million in gross proceeds from warrant exercises provides further financial flexibility.
• The funds will support working capital, research and development, and capital expenditures.
• Shareholder approval was obtained for the issuance of securities.
• The warrants are linked to a clinical milestone, potentially incentivizing progress in OpRegen development.

Negatives

• There is no guarantee that the warrants will be exercised on a cash basis, or at all.
• The company is reliant on achieving the OpRegen clinical milestone to potentially unlock the full $36 million from warrant exercises.

Risks

• The company's ability to secure the full $66 million depends on the exercise of warrants, which is not guaranteed.
• Failure to achieve the OpRegen clinical milestone could result in the warrants expiring unexercised.
• The company's future success depends on the progress of its research and development programs.
• The company is subject to the risks and uncertainties inherent in the biotechnology industry.

Future Outlook

Lineage may receive up to an additional $36 million of gross proceeds upon the exercise in full on a cash basis of the clinical milestone-linked warrants issued in the offering, and plans to use the net proceeds from the offering for working capital and general corporate purposes, including research and development expenses and capital expenditures.

Industry Context

Lineage Cell Therapeutics is operating in the competitive biotechnology industry, focusing on cell therapies. The successful closing of the second tranche of the registered direct offering provides the company with additional capital to advance its pipeline, including OpRegen, OPC1, and ReSonance. The milestone-linked warrants are a common financing tool in the biotech industry, aligning investor incentives with clinical development progress.

Comparison to Industry Standards

• Comparable companies in the cell therapy space, such as Bluebird Bio and CRISPR Therapeutics, often utilize similar financing strategies, including registered direct offerings and milestone-linked warrants.
• The size of the offering ($66 million total) is within the typical range for clinical-stage biotech companies seeking to fund ongoing research and development.
• The warrant exercise price of $0.91 represents a premium over the combined purchase price of $0.76, which is a standard feature of warrant offerings.
• The clinical milestone related to OpRegen is a key value driver for Lineage, and its achievement will likely be critical for warrant exercise and future funding opportunities.

Related Party Transactions

• Broadwood Partners, L.P., an affiliate of Neal Bradsher, a member of Lineage's board of directors, participated in the offering.

Stakeholder Impact

• Shareholders: The offering provides additional capital for the company, potentially increasing shareholder value.
• Employees: The funding supports ongoing research and development efforts, potentially leading to new job opportunities.
• Patients: The development of cell therapies could provide new treatment options for unmet medical needs.
• Roche and Genentech: The collaboration on OpRegen continues, with potential for further development and commercialization.

Next Steps

• Lineage will use the net proceeds for working capital, general corporate purposes, research and development expenses and capital expenditures.
• The company will continue to develop its cell therapy programs, including OpRegen, OPC1, and ReSonance.
• Lineage will monitor the progress of OpRegen and work towards achieving the clinical milestone to potentially unlock the full $36 million from warrant exercises.

Key Dates